S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
3 Secrets To Consistent Trading Success (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
Biden’s Big Lie… (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Biden’s Big Lie… (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:GTHX

G1 Therapeutics - GTHX Stock Forecast, Price & News

$2.68
+0.10 (+3.88%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.60
$2.73
50-Day Range
$2.57
$8.16
52-Week Range
$2.55
$17.49
Volume
822,673 shs
Average Volume
1.09 million shs
Market Capitalization
$138.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60

G1 Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
519.4% Upside
$16.60 Price Target
Short Interest
Bearish
7.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.01mentions of G1 Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$204,976 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.97) to ($1.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

261st out of 996 stocks

Pharmaceutical Preparations Industry

120th out of 484 stocks


GTHX stock logo

About G1 Therapeutics (NASDAQ:GTHX) Stock

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Stock News Headlines

This Tech Stock Could be the Next Amazon
You can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. pixel
Q4 2022 G1 Therapeutics Inc Earnings Call
G1 Therapeutics cuts 30% of workforce
This Tech Stock Could be the Next Amazon
You can learn its name in Luke Lango’s latest report, 5 Hypergrowth Stocks for 2023. Claim Your Free Report Here. pixel
G1 Therapeutics's Earnings Outlook
BTIG Reaffirms Their Buy Rating on G1 Therapeutics (GTHX)
G1 to discontinue study of colorectal cancer treatment
See More Headlines
Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GTHX Company Calendar

Last Earnings
3/01/2023
Today
4/01/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GTHX
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.60
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+519.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-147,560,000.00
Net Margins
-287.63%
Pretax Margin
-284.32%

Debt

Sales & Book Value

Annual Sales
$51.30 million
Book Value
$1.60 per share

Miscellaneous

Free Float
47,479,000
Market Cap
$138.45 million
Optionable
Optionable
Beta
1.83

Key Executives

  • Jack Bailey
    President, Chief Executive Officer & Director
  • Terry L. Murdock
    Chief Operating Officer
  • Jennifer K. Moses
    Chief Financial Officer
  • Rajesh K. MalikRajesh K. Malik
    Chief Medical Officer
  • Mark Avagliano
    Chief Business Officer













GTHX Stock - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GTHX shares.
View GTHX analyst ratings
or view top-rated stocks.

What is G1 Therapeutics' stock price forecast for 2023?

6 equities research analysts have issued twelve-month price objectives for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $25.00. On average, they expect the company's share price to reach $16.60 in the next twelve months. This suggests a possible upside of 519.4% from the stock's current price.
View analysts price targets for GTHX
or view top-rated stocks among Wall Street analysts.

How have GTHX shares performed in 2023?

G1 Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, GTHX shares have decreased by 50.6% and is now trading at $2.68.
View the best growth stocks for 2023 here
.

Are investors shorting G1 Therapeutics?

G1 Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 3,670,000 shares, an increase of 28.3% from the February 28th total of 2,860,000 shares. Based on an average trading volume of 1,260,000 shares, the days-to-cover ratio is presently 2.9 days.
View G1 Therapeutics' Short Interest
.

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our GTHX earnings forecast
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its earnings results on Wednesday, March, 1st. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.85) by $0.12. The business earned $10.25 million during the quarter, compared to analysts' expectations of $9.61 million. G1 Therapeutics had a negative net margin of 287.63% and a negative trailing twelve-month return on equity of 209.92%.

What ETF holds G1 Therapeutics' stock ?

Invesco Nasdaq Future Gen 200 ETF holds 4,161 shares of GTHX stock, representing 0.28% of its portfolio.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $2.68.

How much money does G1 Therapeutics make?

G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $138.45 million and generates $51.30 million in revenue each year. The company earns $-147,560,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

How many employees does G1 Therapeutics have?

The company employs 148 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830.

This page (NASDAQ:GTHX) was last updated on 4/2/2023 by MarketBeat.com Staff